文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

全球脊髓灰质炎根除:欧洲现状与下一步行动

Global polio eradication: Where are we in Europe and what next?
PubMed 文献 · Vaccine · 2017-05-03

全球接近根除脊髓灰质炎,2016年仅3国报告37例。欧盟风险虽低但不可忽视,仅用灭活疫苗程序覆盖率高却累积易感者,且不能绝对阻断 silent transmission。欧盟需更新国家防范计划并落实生物安全措施。

要点

  • 2016年全球仅3国报告37例脊髓灰质炎病例,根除尚未完成。
  • 欧盟仅用灭活疫苗程序覆盖率高,但累积易感人群且不能绝对阻断 silent transmission。
  • 欧盟需更新国家防范计划并实施脊髓灰质炎病毒生物安全计划,认证销毁相关材料。

核心结论

  • 世界从未如此接近根除脊髓灰质炎,但根除尚未结束。
  • 欧盟成员国必须保持警惕,为应对脊髓灰质炎事件或暴发制定计划并做好准备。
  • 只要全球实验室和疫苗生产设施中仍存在脊髓灰质炎病毒,根除工作将持续面临挑战。

研究设计与样本

  • 本文为针对欧盟/欧洲经济区脊髓灰质炎根除现状与下一步行动的综述。

主要发现

  • 2016年全球仅3个国家报告37例脊髓灰质炎病例。
  • 欧盟仅用灭活疫苗程序普遍应用并达到满意覆盖率,但持续留下少量累积的易感个体。
  • 近期以色列暴发表明仅用灭活疫苗程序并非脊髓灰质炎病毒 silent transmission 的绝对屏障。
  • 世界卫生组织全球根除脊髓灰质炎行动每年修订的针对无本土脊髓灰质炎病毒传播或持续传播暴发的识别与应对标准操作程序,有助于并挑战欧盟国家更新其国家防范计划。
  • 欧盟/欧洲经济区在脊髓灰质炎风险方面具有特殊性,涉及疫苗接种政策、大型疫苗生产商及来自高风险地区的持续移民。

临床怎么用

  • 欧盟成员国必须保持警惕,为管理脊髓灰质炎事件或暴发制定计划并做好准备。
  • 欧盟成员国正积极参与实施脊髓灰质炎病毒生物安全计划,并认证销毁脊髓灰质炎病毒株和可能受污染的生物材料。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The world was never so close to reach the polio eradication: only 37 cases notified in 2016 in only three countries, but the game is not yet at the end. The risk of polio outbreaks in the EU is smaller than it has ever been in the past, but it is not so small that we can ignore it. The EU MS must remain alert and plan and prepare for managing polio events or outbreaks because of the possible dire consequences. The IPV only vaccination schedule universally applied in EU has achieved satisfactory coverage, but constantly leaving small accumulating pockets of susceptible individuals. Moreover the IPV only schedule is not an absolute barrier against poliovirus silent transmission as demonstrated in the recent Israel outbreak. The availability of annually revised S.O.P. from WHO GPEI on the identification and response of a polio event, without local poliovirus transmission or a polio outbreak with sustained transmission, helps and challenge EU countries to update their polio national preparedness plans. The EU/EEA area, in fact, is a peculiar area regarding the polio risk both for its vaccination policy, the large polio vaccines manufactures and the constant immigration from areas at polio high risk, but also EU include cultural and financial potentials crucial to sustain the polio end game strategy and reach the benefit of a world without polio risk. Poliovirus eradication will continue to be challenged as long as there is the worldwide presence of polioviruses in laboratories and vaccine production plants. Most of the world's OPV vaccines are produced in the EU and many laboratories and research centers store and handle polio viruses. EU Member States are engaged actively in implementing the poliovirus biocontainment plans that are part of the polio eradication strategy and to certify the destruction of poliovirus strains and potentially contaminated biological materials.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Celentano LP, Carrillo-Santisteve P, O'Connor P, et al. Global polio eradication: Where are we in Europe and what next? Vaccine. 2017. PMID: 28477852. doi:10.1016/j.vaccine.2017.04.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。